If you are wondering whether Pfizer's current share price properly reflects its long term potential, the recent share ...
Pfizer (PFE) recently reported a revenue decline tied to weaker COVID product sales and a US$4.4b impairment charge, while signaling a pivot toward obesity drug programs as well as a larger slate of ...
Hosted on MSN
Pfizer's 7% Dividend: Income Gem or Value Trap?
Pfizer's 7% dividend yield ranks among the highest in the healthcare sector, nearly triple the average of the S&P 500. The payout ratio has improved to 89% from over 100% in recent quarters, but ...
Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to ...
Pfizer (NYSE:PFE) received U.S. FDA Priority Review for a supplemental Biologics License Application covering PADCEV plus ...
Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results